We expect investors to focus on updates related to Viking Therapeutics’ VKTX pipeline when it reports first-quarter 2025 results on April 23, after market close. In the last reported quarter, ...

The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Roche Holding AG and Viking Therapeutics. The Motley Fool has a disclosure policy.

Roche’s CT-996 showed 6.1% mean weight loss in just 4 weeks in obese patients without type 2 diabetes. Structure Therapeutics’ GSBR-1290 cut weight by 6.2% over 12 weeks in its Phase 2a ...

We expect investors to focus on updates related to Viking Therapeutics’ VKTX pipeline when it reports first-quarter 2024 results on Apr 24, after market close. In the last reported quarter, the ...

We expect investors to focus on updates related to Viking Therapeutics’ VKTX pipeline when it reports first-quarter 2025 results on April 23, after market close. In the last reported quarter, the ...